Published • loading... • Updated
More data backs Glucotrack long-term implantable CBGM
Summary by Drug Delivery Business
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
More data backs Glucotrack long-term implantable CBGM
Glucotrack 3-year continuous blood glucose monitor (CBGM) Glucotrack (Nasdaq:GCTK) today announced another publication of data supporting its long-term implantable glucose sensor. The latest data, published in The Journal of Diabetes Research, follows a publication last week supporting the system’s feasibility. This study evaluated the long-term accuracy and stability of the fully implantable blood glucose monitoring (CBGM) system in an in-vivo …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
